Tsumura : Business Results for Fiscal Year 2022(with script)
May 16, 2023 at 09:50 am
Share
Business Results for Fiscal 2022
May 10, 2023
TSUMURA & CO.
1
Agenda
01
02
Business Results for Fiscal 2022 and Earnings Forecast for Fiscal 2023
Outlook for China Business
2
2
Business Results for Fiscal 2022 and Earnings Forecast for Fiscal 2023
Director, and CFO
Muneki Handa
Hello, my name is Muneki Handa.
I would like to start by thanking everyone participating here today for their constant support of Tsumura and its activities to promote the use of Kampo.
I would like to start today's presentation by explaining our business results for FY 2022 and our earnings forecast for FY 2023.
3
Agenda
01
FY 2022 Business Results Overview
4
Firstly, I will give an overview of business results in FY 2022.
4
Roadmap for the Realization of the TSUMURA VISION "Cho-WA" 2031
Prescription Kampo
Products
1st stage
FY2022-2024
-Germination-
Standardization of Kampo
treatments
Personalized Kampo
treatments
Personalized Kampo
2nd stage
FY2025-2027
-Growth-
Over 50% physicians write 10 or more Kampo prescriptions
3rd stage
FY2028-2031
-Flowering-
50% of physicians write basic
prescriptions in all treatment areas
R&D
Formulation
platform
China
Crude drug
Business
platform
Research
platform
Smart factory
Sales
Labor
productivity
Production
Crude drugs
treatments
Research
Scientific study of pre-
symptomatic diseases
Traditional Chinese
Market
medical products business
entry
Crude drugs, drug pieces and
Sales
Yakushokudogen products
expansion
Traditional Chinese Medicine
Establishment
Research Center
Expand scope of
automation
Sales per MR (Yen/MR)
Physical labor productivity
Personnel expenses per crude drug arranging volume
Development
Build
foundations
Establish brands
Function expansion
Shift to oversight/management
Social
implementation
Establish brands
Lead industry development
Evidence-building for traditional
Chinese medical products
Realize smart factories
Double productivity
(vs. FY2021)
5
This is our roadmap we announced in May 2022 for realizing the TSUMURA VISION "Cho-WA" 2031.
The First Medium-Term Management Plan, which spans the three fiscal years up to FY 2024, is positioned as a stage for conducting upfront investments and building foundations to realize our vision.
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tsumura & Co. published this content on 16 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 May 2023 08:49:09 UTC.
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
TSUMURA & CO. 
